AbbVie (ABBV) Wins Health Canada Approval for Boey
AbbVie (ABBV) announced that Health Canada approved Boey for temporary improvement of moderate to severe frown lines in adults, making it the first and only approved botulinum toxin for this indication in Canada.
AbbVie Inc. (NYSE:ABBV) announced on June 23, 2026, that its subsidiary Allergan Aesthetics received Health Canada approval for Boey, a botulinum toxin type A product indicated for the temporary improvement of moderate to severe glabellar lines (frown lines) in adults. Boey is the first and only approved botulinum toxin for this use in Canada.
The Product
Boey is a botulinum toxin type A that temporarily relaxes the muscles responsible for frown lines, reducing their appearance. It is the first treatment approved in Canada specifically for this indication, giving it a first-mover advantage in the Canadian market.
Pricing and Availability
AbbVie has not disclosed pricing or launch details. Boey is expected to be available by prescription through dermatologists and cosmetic physicians.
Competition
The cosmetic botulinum toxin market is competitive, with products like Botox (also from Allergan), Dysport, and Xeomin. However, Boey's unique approval for frown lines in Canada could differentiate it.
Potential Impact on the Company
Boey is expected to strengthen AbbVie's aesthetics portfolio, capitalizing on growing demand for non-invasive procedures. Its impact on revenue will depend on market adoption and pricing strategy.
Frequently Asked Questions
Found this useful? Share it